Report of Foreign Issuer (6-k)
February 14 2018 - 4:16PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February, 2018
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Annual Meeting of Shareholders
GW Pharmaceuticals plc (the “Company”) has announced
that its annual meeting of shareholders will be held on March 14, 2018 (the “Annual Meeting”). In that regard, attached
hereto as Exhibits 99.1 is a copy of the shareholder circular distributed to shareholders on February 14, 2018 in connection with
the Annual Meeting.
The Company’s UK Annual Report (the “UK Annual Report”),
which contains the Company’s Directors’ Remuneration Report for the year ended September 30, 2017, is being mailed
to the Company’s shareholders and also posted on the investor relations section of the Company’s website, www.gwpharm.com.
Shareholders may also go to the Investor Relations page of the Company’s website for a copy of the Annual Report on Form
20-F for the year ended September 30, 2017, as well as copies of the Proxy Statement and form of Proxy Card for the Annual Meeting.
Please note that the form of Proxy Card on the website is for information purposes only and cannot be used to vote.
The information contained in Exhibit 99.1 shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly
set forth by specific reference in such a filing.
Exhibits
|
|
|
99.1
|
|
Shareholder Circular
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Company Secretary
|
|
|
|
Date: February 14, 2018
|
|
|